MX2011009456A - Uso de lactoles de rosuvastatina como medicamentos. - Google Patents

Uso de lactoles de rosuvastatina como medicamentos.

Info

Publication number
MX2011009456A
MX2011009456A MX2011009456A MX2011009456A MX2011009456A MX 2011009456 A MX2011009456 A MX 2011009456A MX 2011009456 A MX2011009456 A MX 2011009456A MX 2011009456 A MX2011009456 A MX 2011009456A MX 2011009456 A MX2011009456 A MX 2011009456A
Authority
MX
Mexico
Prior art keywords
medicaments
rosuvastatin
lactols
relates
rosuvastatin lactols
Prior art date
Application number
MX2011009456A
Other languages
English (en)
Inventor
Peter Jackson
Derek Lindsay
Original Assignee
Bradford Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Pharma Ltd filed Critical Bradford Pharma Ltd
Publication of MX2011009456A publication Critical patent/MX2011009456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Esta invención se refiere al descubrimiento de novedosos análogos de rosuvastatina; más específicamente, la invención se refiere a novedosos análogos de rosuvastatina que tienen utilidad en el tratamiento de condiciones que son tratables con la inhibición de HMG-CoA reductasa.
MX2011009456A 2009-03-10 2010-03-10 Uso de lactoles de rosuvastatina como medicamentos. MX2011009456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904100.5A GB0904100D0 (en) 2009-03-10 2009-03-10 Use of rosuvastatin lactols as medicaments
PCT/GB2010/050409 WO2010103320A1 (en) 2009-03-10 2010-03-10 Use of rosuvastatin lactols as medicaments

Publications (1)

Publication Number Publication Date
MX2011009456A true MX2011009456A (es) 2012-04-10

Family

ID=40600801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009456A MX2011009456A (es) 2009-03-10 2010-03-10 Uso de lactoles de rosuvastatina como medicamentos.

Country Status (19)

Country Link
US (2) US20120004408A1 (es)
EP (1) EP2405972B1 (es)
JP (1) JP5765739B2 (es)
KR (1) KR20110128194A (es)
CN (1) CN102387837B (es)
AU (1) AU2010222658B2 (es)
BR (1) BRPI1009442A2 (es)
CA (1) CA2754825A1 (es)
DK (1) DK2405972T3 (es)
EA (1) EA022783B1 (es)
ES (1) ES2409406T3 (es)
GB (1) GB0904100D0 (es)
IL (1) IL215039A (es)
MX (1) MX2011009456A (es)
NZ (1) NZ595116A (es)
PL (1) PL2405972T3 (es)
PT (1) PT2405972E (es)
WO (1) WO2010103320A1 (es)
ZA (1) ZA201107053B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
GB0904102D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of atorvastatin lactols as medicaments
GB0904104D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
WO2014045294A1 (en) * 2012-09-20 2014-03-27 Inogent Laboratories Private Limited A novel process for the preparation of rosuvastatin calcium using novel intermediates
KR20160072154A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
JP2016536296A (ja) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
US9102655B2 (en) 2013-10-17 2015-08-11 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN104293849A (zh) * 2014-06-10 2015-01-21 常州金隆生物医药有限公司 一种瑞舒伐他汀钙的制备方法
EP3174856A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US10467988B2 (en) * 2015-02-25 2019-11-05 Rockwell Automation Asia Pacific Business Center Pte. Ltd. Amalgamated alphanumeric character display system and method
PL124682U1 (pl) * 2015-12-16 2017-06-19 Ewa Edyta Bujak Zestaw rehabilitacyjny układanki sensorycznej, zwłaszcza dla dzieci z zaburzeniami psychomotorycznymi
EP3737676B1 (en) * 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
ATE132496T1 (de) * 1987-07-10 1996-01-15 Hoechst Ag 3-desmethyl-mevalonsäurederivate, verfahren zu ihrer herstellung, pharmazeutische präparate auf basis dieser verbindungen, ihre verwendung sowie zwischenprodukte
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO2005012246A1 (en) * 2003-07-25 2005-02-10 Avecia Pharmaceuticals Limited Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
DE102005022284A1 (de) * 2005-05-13 2006-11-23 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen
EP1834944A1 (en) * 2006-03-17 2007-09-19 Ratiopharm GmbH Process for preparing C7 intermediates and their use in the preparation on N-substituted pyrrole derivatives
GB0904104D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives
GB0904100D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
GB0904102D0 (en) 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of atorvastatin lactols as medicaments

Also Published As

Publication number Publication date
DK2405972T3 (da) 2013-06-10
EP2405972B1 (en) 2013-03-06
KR20110128194A (ko) 2011-11-28
US20140018381A1 (en) 2014-01-16
WO2010103320A1 (en) 2010-09-16
NZ595116A (en) 2013-02-22
EP2405972A1 (en) 2012-01-18
CA2754825A1 (en) 2010-09-16
JP2012520281A (ja) 2012-09-06
GB0904100D0 (en) 2009-04-22
CN102387837A (zh) 2012-03-21
PL2405972T3 (pl) 2013-10-31
US9102656B2 (en) 2015-08-11
ZA201107053B (en) 2014-03-26
AU2010222658B2 (en) 2014-10-02
CN102387837B (zh) 2015-11-25
EA022783B1 (ru) 2016-03-31
JP5765739B2 (ja) 2015-08-19
ES2409406T3 (es) 2013-06-26
EA201101194A1 (ru) 2012-04-30
IL215039A0 (en) 2011-11-30
AU2010222658A1 (en) 2011-09-29
IL215039A (en) 2014-12-31
PT2405972E (pt) 2013-06-05
US20120004408A1 (en) 2012-01-05
BRPI1009442A2 (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
MX2011009456A (es) Uso de lactoles de rosuvastatina como medicamentos.
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
WO2013163190A8 (en) Dna-pk inhibitors
IN2012DN03883A (es)
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
IN2012DN01641A (es)
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2012004780A (es) Inhibidores de akt.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
IN2012DN01642A (es)
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
WO2011041311A3 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
MX2009005938A (es) 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
WO2012017321A3 (en) Treatment for dyslipidemia
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2011009458A (es) Derivados de rosuvastatina y atorvastatina.
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
WO2011083495A8 (en) Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds
MX2011009457A (es) Uso de lactoles de atorvastatina como medicamentos.
MX2011010046A (es) Derivados de diaminopteridina.

Legal Events

Date Code Title Description
FG Grant or registration